CYPRUMED

Austria
Obsteig, Tyrol, Austria, 6416

Company profile

CYPRUMED company profile

CYPRUMED® is a biopharmaceutical company developing a next generation platform technology for the oral delivery of polypeptides. The patent pending technology is entirely based on GRAS listed compounds and easy to formulate. In vivo studies with various polypeptide drugs in rodents, dogs and none human primates showed oral bioavailability up to 70% (rel. s.c.).

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2015-01-01, Year

Headquarters

Postal code
6416
Country code
AT
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
1
Total equity funding
$1.1M
Last funding
Seed / $1.1M / 2016-02-03
Last equity funding
Seed / $1.1M
Founders
1
Articles
8

Founders and investors

Founders

Florian Föger